Thrasos Therapeutics logo
Exited company

Thrasos Therapeutics

Industry sector
Investment year
Healthcare Venture Fund
Learn more
About the company

Thrasos is a private, clinical‑stage biotherapeutics company focused on delivering new solutions to individuals affected by kidney disease. The company has two major programs; its lead program targets acute kidney injury (AKI) while the second program addresses diabetic nephropathy, a leading cause of chronic kidney disease (CKD).

Your privacy

BDC uses cookies to improve your experience on its website and for advertising purposes, to offer you products or services that are relevant to you. By clicking ῝I understand῎ or by continuing to browse this site, you consent to their use.

To find out more, consult our Policy on confidentiality.